Share Price

Conference Call with Shilpa Medicare Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 week 5 days ago

Pharmaceuticals company Shilpa Medicare announced Q4FY26 & FY26 results Standalone Financial Highlights: Revenue from Operations: Q4FY26: Rs 20,111 lakh, compared to Rs 16,686 lakh in Q3FY26 (QoQ increase of 20.53%) and Rs 12,621 lakh in Q4FY25 (YoY increase of 59.35%). FY26: Rs 59,703 lakh, compared to Rs 47,741 lakh in FY25 (YoY increase of 25.05%). Total Income: Q4FY26: Rs 20,800 lakh, compared to Rs 17,310 lakh in Q3FY26 (QoQ increase of 20.16%) and Rs 13,685 lakh in Q4FY25 (YoY increase of 52.00%). FY26: Rs 63,517 lakh, compared to Rs 54,708 lakh in FY25 (YoY increase of 16.10%). Net Profit After Tax: Q4FY26: Rs 7,096 lakh, compared to Rs 1,411 lakh in Q3FY26 (QoQ increase of 402.91%) and Rs (563) lakh in Q4FY25. FY26: Rs 13,297 lakh, compared to Rs 6,789 lakh in FY25 (YoY increase of 95.86%). Consolidated Financial Highlights: Revenue from Operations: Q4FY26: Rs 43,699 lakh, compared to Rs 41,028 lakh in Q3FY26 (QoQ increase of 13.07%) and Rs 33,082 lakh in Q4FY25 (YoY decrease of 4.13%). FY26: Rs 153,887 lakh, compared to Rs 128,643 lakh in FY25 (YoY increase of 13.30%). Total Income: Q4FY26: Rs 43,866 lakh, compared to Rs 41,054 lakh in Q3FY26 (QoQ increase of 12.29%) and Rs 33,845 lakh in Q4FY25 (YoY decrease of 3.64%). FY26: Rs 154,871 lakh, compared to Rs 130,976 lakh in FY25 (YoY increase of 13.47%). Net Profit After Tax: Q4FY26: Rs 10,779 lakh, compared to Rs 4,458 lakh in Q3FY26 (QoQ increase of 39.37%) and Rs 1,451 lakh in Q4FY25 (YoY increase of 61.03%). FY26: Rs 24,333 lakh, compared to Rs 7,829 lakh in FY25 (YoY increase of 47.52%). Business Highlights: Dividend: The Board recommended a final dividend of Re. 0.60 per equity share (60% on the face value of Re. 1/- each) for the financial year 2025-26, subject to approval at the ensuing Annual General Meeting. Registered Office Shifting: The Board approved the shifting of the registered office from Raichur, Karnataka, to the state of Maharashtra, subject to member approval via Postal Ballot. Strategic Investments: The Company and its wholly-owned subsidiaries (SPL, SBPL, Biocare) approved an equity investment of 28% in Neo Green Power Project Private Limited to meet captive power consumption requirements. Auditor Appointments: M/s. V.J. Talati & Co., Cost Accountants, appointed as Cost Auditors for FY27. M/s. Aneja Associates, appointed as Internal Auditors for FY27. Segment Information: The Company operates in the manufacturing of products of the same type/class and is considered to have a single reportable segment, "Pharmaceuticals." Labour Codes: In compliance with new Labour Codes, the Company recognized past service costs amounting to Rs 103.09 lakh (previous quarter) and Rs 96.81 lakh (current quarter) within employee benefit expenses. Result PDF

• Trendlyne
• 1 week 5 days ago

Pharmaceuticals company Shilpa Medicare announced Q3FY26 results Revenue: Rs 411 crore against Rs 321 crore during Q3FY25, change 28%. EBITDA: Rs 115 crore against Rs 82 crore during Q3FY25, change 40%. EBITDA Margin: 28% for Q3FY26. PBT: Rs 277 crore against Rs 230 crore during Q3FY25, change 20%. PBT Margin: 68% for Q3FY26. PAT: Rs 55 crore against Rs 32 crore during Q3FY25, change 72%. PAT Margin: 13% for Q3FY26. Vishnukant Bhutada, Managing Director, said: Building on our strong beginning to FY26, we continue to make considerable progress across all our verticals. In 3QFY26, we delivered 28% (YoY) revenue growth with EBITDA margins of 28%, achieving our highest quarterly revenue and EBITDA. Our differentiated R&D-driven; business model is centered on developing highvalue, limited-competition products. During the quarter we secured EU approval for Rotigotine and successfully completed Phase 3 trials for Ondansetron ER in India. We successfully launched a novel, first-in-class therapy for NAFLD in India under our own label, while also partnering with three large pharma companies to maximize commercial reach. The initial response from both partners and physicians has been highly encouraging as reflected in Domestic FDF segment revenue. We are now advancing global regulatory efforts to bring this vital therapy to patients internationally. Our FDF vertical grew by 50% YoY, driven by strong traction in our EU business which reported over 100% (YoY) revenue growth, coupled with improved traction in Domestic formulations and sustained market share gains for our 505(b)(2) assets in the US. API non-oncology growth was supported by newly expanded capacities. In Biologics, we see strong traction with steady progress in key pipeline assets. The operational momentum is also translating into improved capital efficiency, as seen in our improving ROCE. With a solid R&D; foundation, key product approvals, clear launch timelines, and strategic partnerships that drive market share expansion of our critical products, we are confident in a significantly better FY27. Result PDF

• Trendlyne
• 3 months 3 weeks ago